Table 2.
Clinical outcomes between hyperbilirubinemia and non-hyperbilirubinemia groups before propensity score matching.
| Parameters | Full cohort | P | |
|---|---|---|---|
| Hyperbilirubinemia group | No-hyperbilirubinemia group | ||
| (n = 544) | (n = 2,240) | ||
| Serum total bilirubin levels during the course of disease (mg/dL), n (%) | <0.001 | ||
| Serum total bilirubin at 0–1.9 mg/dL | 0 (0) | 2240 (100.0) | |
| Serum total bilirubin at 2–4.9 mg/dL | 338 (62.1) | 0 | |
| Serum total bilirubin at 5–10 mg/dL | 141 (25.9) | 0 | |
| Serum total bilirubin at >10 mg/dL | 65 (11.9) | 0 | |
| The life support | |||
| Vasopressor usage, n (%) | 251 (46.1) | 878 (39.2) | 0.003 |
| Mechanical ventilation, n (%) | 273 (50.2) | 1208 (53.9) | 0.125 |
| Sedative drug usage | 271 (49.8) | 1143 (51.0) | 0.633 |
| AKI KDIGO stage, n (%) | 0.097 | ||
| AKI at 1 stage | 118 (21.7) | 532 (23.8) | |
| AKI at 2 stage | 171 (31.4) | 617 (27.5) | |
| AKI at 3 stage | 101 (18.6) | 370 (16.6) | |
| Clinical outcomes | |||
| In-hospital mortality, n (%) | 88 (16.2) | 240 (10.7) | 0.002 |
| 30 d mortality, n (%) | 118 (21.7) | 364 (16.3) | 0.011 |
| 90 d mortality, n (%) | 138 (25.4) | 437 (19.5) | 0.010 |
| 180 d mortality, n (%) | 148 (27.2) | 495 (22.1) | 0.039 |
| One-year mortality, n (%) | 162 (29.8) | 548 (24.5) | 0.037 |
Categorical variables are reported as count (% of column total).
Abbreviations: AKI acute kidney injury, KDIGO the Kidney Disease: Improving Global Outcomes.